Allogeneic hematopoietic stem cell transplantation is the only treatment method to cure hematologic malignancies. However

difficulty in obtaining the human leukocyte antigen (HLA) match donors is a major limitation in this therapeutic strategy. Many studies have demonstrated that umbilical cord blood is rich in hematopoietic stem cells and can be used as a source of stem cells of hematopoietic stem cell transplantation. Growing evidence also supports the efficacy of cord blood transplantation (CBT) to treat patients with haematological malignancies

and the number of CBTs is rapidly increasing. Compared to other sources of stem cells

umbilical cord blood is physical cryopreserved. Therefore

it is very convenient for transplantation

particular for those who need to receive transplantation sooner. In addition

the incidence and severity of graft versus host disease(GVHD) in CBT are usually relatively lower. Herein

we review considerations regarding status

research progresses and selection of umbilical cord blood in CBT.